z-logo
open-access-imgOpen Access
Microglia in Alzheimer's disease at single-cell level. Are there common patterns in humans and mice?
Author(s) -
Yun Chen,
Marco Colonna
Publication year - 2021
Publication title -
the journal of experimental medicine/the journal of experimental medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 8.483
H-Index - 448
eISSN - 1540-9538
pISSN - 0022-1007
DOI - 10.1084/jem.20202717
Subject(s) - microglia , neurodegeneration , neuroinflammation , biology , neuroscience , alzheimer's disease , amyloid (mycology) , sandhoff disease , pathogenesis , senile plaques , disease , immunology , inflammation , pathology , medicine , gene , genetics , botany
Alzheimer’s disease (AD) is characterized by extracellular aggregates of amyloid β peptides, intraneuronal tau aggregates, and neuronal death. This pathology triggers activation of microglia. Because variants of genes expressed in microglia correlate with AD risk, microglial response to pathology plausibly impacts disease course. In mouse AD models, single-cell RNA sequencing (scRNA-seq) analyses delineated this response as progressive conversion of homeostatic microglia into disease-associated microglia (DAM); additional reactive microglial populations have been reported in other models of neurodegeneration and neuroinflammation. We review all of these microglial signatures, highlighting four fundamental patterns: DAM, IFN–microglia, MHC-II microglia, and proliferating microglia. We propose that all reported microglia populations are either just one or a combination, depending on the clustering strategy applied and the disease model. We further review single-nucleus RNA sequencing (snRNA-seq) data from human AD specimens and discuss reasons for parallels and discrepancies between human and mouse transcriptional profiles. Finally, we outline future directions for delineating the microglial impact in AD pathogenesis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here